CRYSTALLINE FORMS OF (9R, 135S)-13- {4-[5-CHLORO-2-(4-CHLORO-1H,2,3- TRIAZOL- 1 -YL)PHENYL] -6-OXO- 1,6-DIHYDROPYRIMIDIN- 1-YL}-3-(DIFLUOROMETHYL)-9-METHYL-3,4,7,15- TETRAAZATRICYCLO [ 12.3.1.02·6] OCTADECA- 1(18), 2(6), 4, 14, 16-PENTAEN-8-ONE

Disclosed are crystalline forms of Compound (I). Compound (I) is useful as an anti-thromboembolic agent in the treatment of cardiovascular diseases. L'invention concerne des formes cristallines du composé (I). Le composé (I) est utile en tant qu'agent anti-thromboembolique dans le traiteme...

Full description

Saved in:
Bibliographic Details
Main Authors SMITH, Daniel, CLEEREN, Dirk Angelina J, DILGER, Andrew K, AHUJA, Dipali, ZIEMBA, Theresa M, XIOURAS, Christos, LÜDEKER, David, GALELLA, Michael A
Format Patent
LanguageEnglish
French
Published 14.10.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Disclosed are crystalline forms of Compound (I). Compound (I) is useful as an anti-thromboembolic agent in the treatment of cardiovascular diseases. L'invention concerne des formes cristallines du composé (I). Le composé (I) est utile en tant qu'agent anti-thromboembolique dans le traitement de maladies cardiovasculaires.
Bibliography:Application Number: WO2021US26663